XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Financial Instruments (Tables)
6 Months Ended
Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Effect of Net Investment Hedges on OCI and the Consolidated Statement of Operations
The effects of the Company’s net investment hedges on OCI and the Condensed Consolidated Statement of Operations are shown below:
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Three Months Ended June 30,Six Months Ended June 30,Three Months Ended June 30,Six Months Ended June 30,
($ in millions)20232022202320222023202220232022
Net Investment Hedging Relationships
Foreign exchange contracts$— $(31)$$(46)$— $(1)$$(2)
Euro-denominated notes21 (128)73 (181)— — — — 
(1)    No amounts were reclassified from AOCL into income related to the sale of a subsidiary.
Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:
  June 30, 2023December 31, 2022
  Fair Value of DerivativeU.S. Dollar
Notional
Fair Value of DerivativeU.S. Dollar
Notional
($ in millions)AssetLiabilityAssetLiability
Derivatives Designated as Hedging InstrumentsBalance Sheet Caption
Foreign exchange contractsOther current assets$200 $— $5,976 $220 $— $4,824 
Foreign exchange contractsOther Assets43 — 1,750 27 — 1,609 
Foreign exchange contractsAccrued and other current liabilities— 62 2,245 — 101 2,691 
Foreign exchange contractsOther Noncurrent Liabilities— 328 — 91 
  $243 $63 $10,299 $247 $102 $9,215 
Derivatives Not Designated as Hedging InstrumentsBalance Sheet Caption      
Foreign exchange contractsOther current assets$222 $— $8,838 $186 $— $8,540 
Foreign exchange contractsAccrued and other current liabilities— 181 10,112 — 307 10,926 
  $222 $181 $18,950 $186 $307 $19,466 
  $465 $244 $29,249 $433 $409 $28,681 
Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
 June 30, 2023December 31, 2022
($ in millions)AssetLiabilityAssetLiability
Gross amounts recognized in the condensed consolidated balance sheet$465 $244 $433 $409 
Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet(180)(180)(220)(220)
Cash collateral received/posted(102)— (66)(19)
Net amounts$183 $64 $147 $170 
Location and Amount of Pretax Gains and Losses of Derivatives
The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:
Three Months Ended June 30,Six Months Ended June 30,
($ in millions)202320222023202220232022202320222023202220232022
Financial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are RecordedSales
Other (income) expense, net (1)
Other comprehensive income (loss)Sales
Other (income) expense, net (1)
Other comprehensive income (loss)
$15,035 $14,593 $172 $438 $(17)$42 $29,522 $30,494 $259 $1,148 $(132)$102 
(Gain) loss on fair value hedging relationships:
Interest rate swap contracts
Hedged items— — — (4)— — — — — (14)— — 
Derivatives designated as hedging instruments— — — — — — — — — — 
Impact of cash flow hedging relationships:
Foreign exchange contracts
Amount of gain recognized in OCI on derivatives
— — — — 194 403 — — — — 128 551 
Increase in Sales as a result of AOCL reclassifications
24 172 — — (24)(172)125 239 — — (125)(239)
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
— — — — — — — — (1)(1)— — 
Amount of gain (loss) recognized in OCI on derivatives
— — — — 13 — — — — — 13 (1)
(1)    Interest expense is a component of Other (income) expense, net.
Income Statement Effects of Derivatives Not Designated as Hedging Instruments
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax (Gain) Loss Recognized in Income
Three Months Ended June 30,Six Months Ended June 30,
($ in millions)2023202220232022
Derivatives Not Designated as Hedging InstrumentsIncome Statement Caption
Foreign exchange contracts (1)
Other (income) expense, net$(41)$(64)$(28)$(36)
Foreign exchange contracts (2)
Sales(5)(36)(3)(38)
(1)    These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.
(2)    These derivative contracts serve as economic hedges of forecasted transactions.
Information on Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
 June 30, 2023December 31, 2022
 Amortized
Cost
Gross UnrealizedFair
Value
Amortized
Cost
Gross UnrealizedFair
Value
($ in millions)GainsLossesGainsLosses
Commercial paper$561 $— $— $561 $498 $— $— $498 
U.S. government and agency securities256 — — 256 68 — — 68 
Corporate notes and bonds— — — — 
Total debt securities$821 $— $— $821 $569 $— $— $569 
Publicly traded equity securities (1)
1,520 1,284 
Total debt and publicly traded equity securities$2,341 $1,853 
(1)    Unrealized net losses (gains) of $71 million and $(267) million were recorded in Other (income) expense, net in the second quarter and first six months of 2023, respectively, on equity securities still held at June 30, 2023. Unrealized net (gains) losses of $(25) million and $194 million were recorded in Other (income) expense, net in the second quarter and first six months of 2022, respectively, on equity securities still held at June 30, 2022.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
Fair Value Measurements UsingFair Value Measurements Using
 Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
($ in millions)June 30, 2023December 31, 2022
Assets
Investments
Commercial paper$— $561 $— $561 $— $498 $— $498 
U.S. government and agency securities— 187 — 187 — — — — 
Publicly traded equity securities1,184 — — 1,184 1,015 — — 1,015 
 1,184 748 — 1,932 1,015 498 — 1,513 
Other assets (1)
U.S. government and agency securities69 — — 69 68 — — 68 
Corporate notes and bonds— — — — 
Publicly traded equity securities336 — — 336 269 — — 269 
409 — — 409 340 — — 340 
Derivative assets (2)
Forward exchange contracts— 316 — 316 — 218 — 218 
Purchased currency options— 149 — 149 — 215 — 215 
 — 465 — 465 — 433 — 433 
Total assets$1,593 $1,213 $— $2,806 $1,355 $931 $— $2,286 
Liabilities
Other liabilities
Contingent consideration$— $— $349 $349 $— $— $456 $456 
Derivative liabilities (2)
Forward exchange contracts— 235 — 235 — 402 — 402 
Written currency options— — — — 
— 244 — 244 — 409 — 409 
Total liabilities$— $244 $349 $593 $— $409 $456 $865 
(1)    Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(2)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
Information About the Changes in Liabilities for Contingent Consideration
Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:
($ in millions)20232022
Fair value January 1$456 $777 
Changes in estimated fair value (1)
10 (114)
Payments(117)(119)
Other— (2)
Fair value June 30 (2)
$349 $542 
(1)    Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2)    At June 30, 2023, $262 million of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at June 30, 2023 includes $130 million recorded as a current liability for amounts expected to be paid within the next 12 months.